LPGO — Lipigon Pharmaceuticals AB Cashflow Statement
0.000.00%
Last trade - 00:00- SEK16.24m
- SEK4.47m
- SEK20.57m
Annual cashflow statement for Lipigon Pharmaceuticals AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | SAS | SAS | SAS | SAS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -7.82 | -41.2 | -37.7 | -12.4 | -26.5 |
| Depreciation | |||||
| Non-Cash Items | — | -0.243 | -0.023 | 0.093 | -0.283 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.801 | 6.11 | 0.274 | -2.05 | 1.96 |
| Change in Accounts Receivable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -17.3 | -70.6 | -74.9 | -28.6 | -49.6 |
| Capital Expenditures | — | -0.119 | 0 | — | -0.235 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 1.25 | — | — | — | — |
| Sale/Maturity of Investment | |||||
| Cash from Investing Activities | 2.5 | -0.238 | 0 | — | -0.47 |
| Financing Cash Flow Items | -0.769 | -5.22 | -3.99 | -6.56 | -0.26 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 37.8 | 102 | 37.2 | 73.4 | 9.16 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 11.5 | 15.9 | -18.8 | 22.3 | -20.2 |